evaluation of the efficacy of respicure® (resveratrol / quercetin) in the management of respiratory conditions including asthma,copd and long covid.

Conditions: Asthma; Chronic Obstructive Pulmonary Disease; Long COVID

Summary: interventional, prospective, national, multicentre, randomised, open-label, controlled clinical study comparing two parallel groups, one control arm (standard treatment) versus intervention arm (standard treatment + study product) evaluating the efficacy of respicure® 0.38% /0.38% (resveratrol / quercetin) phytotherapy product from beker laboratories as an add-on treatment in the management of respiratory conditions including asthma (partially controlled),copd (stage a, b, c and d) and long covid in algerian adult patients .

this is an interventional, prospective, national, multicenteric, randomized, open-label, controlled clinical study comparing two arms: control arm taking the standard of care versus intervention arm (standard of care + respicure®). a total of 480 patients (160 in each group of pathology i.e asthme, copd and long covid, distributed through 8 centers resulting in 20 patients/center for each group of pathology). the administration of the study product is by randomaisation.the data will be collected during 5 visits for the two arms as following: * visit v1 on d0: inclusion, signature of informed consent and implementation of the respire dz protocol with delivery to patients of a one-month supply of respicure® for the intervention arm, * intermediary visit on d15: face-to-face and/or by telephone to assess safety after the use of respicure® for the intervention arm. * visit v2 on d30: follow-up visit with delivery to patients of a one-month supply of respicure® for the intervention arm, * visit v3 on d60: follow-up visit with delivery to patients of a one-month supply of respicure® for the intervention arm, * visit v4 at d90:follow-up visit at the end of the use of the study product, * visit v5 at d180: follow-up and end-of-study visit.

Eligibility criteria:
* inclusion criteria for asthma patients: 1. male, female, aged ≥19. 2. being able to provide written informed consent before the study. 3. patient with partially controlled asthma: assessment of asthma control over the month preceding the use of respicure ® by a symptomatic assessment (tick one or two symptoms): 3. 1 daytime symptoms more than twice a week, 3. 2 one or more nocturnal awakenings, 3. 3 need for rescue medication more than twice a week, 3. 4 one or more activity limitations 4. patient followed for at least a year and mastering the technique of using devices i.e. aerosols, nebulizer etc... * inclusion criteria for copd patients: 1. male, female, ≥40 years old 2. being able to provide written informed consent before the study. 3. patient with copd stage a, b, c or d in stable condition with no exacerbations in the past 4 weeks. 4. patient followed for at least a year and mastering the technique of using devices i.e. aerosols, nebulizer etc... * inclusion criteria for long covid patients: 1. male, female, aged ≥19. 2. being able to provide written informed consent before the study. 3. patients followed for respiratory symptoms linked to long covid (symptoms for more than 12 weeks). exclusion criteria : 1. patient with severe asthma (for asthma groupe only) 2. prior use of respicure®. 3. concomitant use with the following products: cytochrome p450 3a4 substrate drugs (e.g. statin, antifungals and fexofenadine), antibiotics (quinolones), immunosuppressants (cyclosporine) and glycoprotein p substrate drugs, e.g. antifungal and antiarrhythmic . 4. hypersensitivity to any of the ingredients. 5. hypersensitivity to peanuts. 6. concomitant intake of a product containing one or both of the active ingredients (resveratrol/quercetine). 7. pregnancy/ lactation. 8. people who need to undergo surgery. 9. participation in another clinical study within the previous 30 days. 10. patient with asthma-copd overlap syndrome or any other respiratory disease such as pneumonia, tuberculosis, pulmonary embolism, etc. 11. hormone-sensitive conditions such as breast cancer, uterine cancer, ovarian cancer, endometriosis or uterine fibroids. 12. patients requiring admission to intensive care and/or requiring respiratory assistance. 13. patients requiring anticoagulant treatment at curative doses.

Keywords: phytotherapy inhalation complementary medicine